Today, the Food and Drug Administration (“FDA”) announced it is withdrawing the Compliance Policy Guide (“CPG”) entitled, “Conditions Under Which Homeopathic Drugs May be Marketed,” which was issued in 1988 and describes the agency’s enforcement policy for such products. The withdrawal is applicable today. The FDA is implementing a risk-based enforcement policy in its place. […]
Jonathan Emord appeared for two hours on the nationally syndicated radio program “Coast to Coast” with George Noory on September 9, 2019 from 9PM to Midnight Pacific. Jonathan discussed the opioid crisis, FDA complicity in the acts of major pharmaceutical companies in promotions that caused it, Trump’s efforts to stem the crisis, the Oklahoma public […]
For Immediate Release: 23 August 2017 Contact: Dr. Linda Lagemann, Liaison to the Petitioners (415-640-7343) Attorney Jonathan Emord and his co-counsel Kendrick Moxon have filed a Supplement to their Citizen Petition of August 2016, protesting the FDA’s Proposed Order to reclassify and make more readily available the Electroconvulsive Therapy (ECT) Device used to give […]
Read Jonathan Emord’s October 12, 2016 article in the Washington Times concerning the FDA’s untenable decision to downgrade Electroconvulsive Therapy (ECT) medical devices from Class III to Class II: The FDA’s bow to barbarism: Downgrading the brain injury risks from shock therapy is unjustified (Oct. 12, 2016) (opens in new window)
Huffingtonpost.com: FDA, Straighten Up! Attorney Jonathan Emord takes on FDA over shock therapy (ECT) (link opens in new window) Click the above link to read Dr. Linda Lagemann’s August 26, 2016 article.
For Immediate Release Contact: Dr. Linda Lagemann 415-640-7343 Email: 2DrLagemann@gmail.com Attorney Jonathan Emord Takes on the FDA Over Electroshock (ECT) Device In December 2015, the FDA issued a proposed order to down-classify the device used to deliver electroshock therapy. Today, Attorney Jonathan Emord filed a Citizens Petition with the FDA on behalf of 5 individuals […]
By Eric Awerbuch In April, 2014, five members of Congress introduced a bill, H.R. 4432 (hereinafter “the Bill”) seeking to regulate, among other things, the labeling of bio-engineered food products.[i] The Bill, also known as the “Safe and Accurate Food Labeling Act of 2014,” is remarkable in that it: 1) prohibits the States from […]
Tim Delmastro, the director and co-producer of Freedom From Choice, winner of the Best International Documentary award, will be interviewed tomorrow night on the Stossel Show about his feature-length film. Freedom From Choice investigates the loss of our liberties. It asks whether our daily choices, from what we eat to what we read, are in […]
President Obama signed the Drug Quality and Security Act (“DQSA”) into law on November 27, 2013. The DQSA contained provisions concerning the oversight of human drug compounding. For instance, it removed provisions of section 503A of the federal Food, Drug, and Cosmetic Act (“FDCA”) that the U.S. Supreme Court previously held were unconstitutional, thereby ensuring […]
Oral arguments concluded on Monday, April 21, 2014, in the POM v. Coke (Dkt. No. 12-761) case pending before the United States Supreme Court. Click here to read what experts had to say about the arguments. To recap, POM originally challenged Coke’s marketing for Minute Maid “Pomegranate Blueberry” fruit juice blend. POM filed a Lanham Act […]
Whether evaluating a concept, performing regulatory due diligence, maintaining or prosecuting regulatory filings, or contesting adverse litigation, Emord & Associates provides exceptional counsel for all your litigation and regulatory needs.
11808 Wolf Run Lane
Clifton, VA 20124
Telephone: (202) 466-6937
Telecopier: (202) 466-6938
